A Phase 3 interventional study of Paclitaxel (Taxane) and Docetaxel (Taxane) in Non-Small-Cell Lung Carcinoma, sponsored by Eli Lilly and Company. Completed at 125 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-12-24.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies testing cetuximab in Carcinoma, Non-Small-Cell Lung — 2 open to participants now, 2 under way, none of them phase 3. Cetuximab · Carcinoma, Non-Small-Cell Lung.
Among the 52 studies testing cetuximab in Carcinoma, Non-Small-Cell Lung, this one is the 3rd largest by enrollment of the 51 interventional ones that give a count, is one of 8 that started in 2004, is one of 5 in phase 3, and was the 10th registered.
7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →2 of the 52 studies testing cetuximab in Carcinoma, Non-Small-Cell Lung are open now, in 2 countries. Recruiting first, the newest first:
Sun Yat-sen University · Sites in China
Ages 18+
Jonathan Riess · Sites in United States
Ages 18+
By country, each count listing its studies:
Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 38 · Phase 3 6
First in 2000; this study’s year is marked. 8 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 755 is above the median of 62 across 6,031 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 63 across the 51 interventional studies. Of the 47 that completed or were terminated, 22 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 52 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 155 are open to participants now.
Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company: 6 open now, 20 under way, 6 of them phase 3. Of 121 finished, 81 (67%) have results posted.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 9th largest by enrollment of the 139 interventional ones that give a count, is one of 8 that started in 2004, is one of 25 in phase 3, and was the 17th registered.
Eli Lilly and Company’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 52 studies testing cetuximab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 147 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this clinical research study is to learn if patients treated with the combination of Taxane/Carboplatin plus Cetuximab (C/T/C) have a longer progression-free survival than patients treated with Taxane/Carboplatin (T/C) alone. The safety of this treatment will also be studied.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cetuximab was administered at an initial dose (Week 1) of 400 mg/m\^2 intravenous (IV) infusion (infused over 120 minutes) and a weekly maintenance dose of 250 mg/m\^2 IV infusion (infused over 60 minutes). A cycle of therapy was defined as 3 weeks. Taxane was paclitaxel 225 mg/m\^2 infused over 180 minutes on Day 1 and subsequently every 3 weeks or docetaxel 75 mg/m\^2 infused over 60 minutes on Day 1 and subsequently every 3 weeks. Carboplatin was infused over 30 minutes on Day 1 and subsequently every 3 weeks.
Drug: Paclitaxel (Taxane) · Drug: Docetaxel (Taxane) · Drug: Carboplatin · Drug: Cetuximab
A cycle of therapy was defined as 3 weeks. Taxane was paclitaxel 225 mg/m\^2 infused over 180 minutes on Day 1 and subsequently every 3 weeks or docetaxel 75 mg/m\^2 infused over 60 minutes on Day 1 and subsequently every 3 weeks. Carboplatin was infused over 30 minutes on Day 1 and subsequently every 3 weeks.
Drug: Paclitaxel (Taxane) · Drug: Docetaxel (Taxane) · Drug: Carboplatin
IV, 225 mg/m\^2
IV, 75 mg/m\^2
AUC=6, q 3 weeks (6 cycles maximum)
Intravenous, 400 mg/m\^2, initial dose followed by 250 mg/m\^2, weekly starting on Week 2
Also known as: Erbitux
Median Number of Months of Progression-free Survival (PFS)
Interval between randomization date \& earliest date of disease progression/death due to any cause, assessed by the Independent Radiology Review Committee (IRRC) using modified World Health Organization (WHO) criteria to define progressive disease (PD): \>=25% increase in sum of products of diameters (SOPD) of lesions compared with smallest SOPD recorded for study period or progression of any non-index lesion/appearance of new lesion. If no progression/death, date of last tumor assessment used. For participants who had no on-study tumor assessments \& were still alive, date of randomization used.
Time frame: From randomization to evidence of disease progression/death or date of last tumor assessment (up to 26 months).
Number of Participants With Complete Response (CR) or Partial Response (PR)
Tumor response was defined as the number of participants whose best response was CR or PR, per the IRRC assessment, using the modified WHO criteria: CR: disappearance of all index/non-index lesions; PR: \>= 50% reduction in the SOPD of index lesions compared with the baseline SOPD, with no evidence of progression. To qualify as CR or PR, no new lesions could be present.
Time frame: From randomization to end of study drug therapy (up to 174 weeks).
Number of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD)
Disease control was defined as the number of participants whose best response was CR, PR, or SD, per the IRRC assessment, using the modified WHO criteria: CR: disappearance of all index/non-index lesions; PR:\>= 50% reduction in the SOPD of index lesions compared with the baseline SOPD, with no evidence of progression (to qualify as CR or PR, no new lesions could be present); SD: participants who did not meet the criteria for CR, PR, or PD (PD:\>=25% increase in SOPD of lesions compared with smallest SOPD recorded for study period or progression of any non-index lesion/appearance of new lesion).
Time frame: From randomization to end of study drug therapy (up to 174 weeks).
Median Number of Months of Response
Median number of months of response (time from first occurrence of CR/PR to date of PD/death, \[per IRRC assessment,using modified WHO criteria\]) calculated for participants whose best response=CR/PR.For participants who did not progress/die, date of last tumor assessment used.CR:disappearance of all index/non-index lesions;PR:\>= 50% reduction in SOPD of index lesions compared with baseline, no evidence of progression.No new lesions present.PD:\>=25% increase in SOPD of lesions compared with smallest SOPD recorded for study period or progression of any non-index lesion/appearance of new lesion.
Time frame: Time from first occurrence of CR or PR (whichever was recorded first) to the date of PD, death or date of last tumor assessment (up to 19 months).
Median Number of Months to Response
The median number of months to response was calculated for participants whose best response was CR or PR. It was defined as the time from the first dose of study therapy to the first date that criteria for PR or CR (whichever occurred first)were met. Response was assessed by the IRRC, using the modified WHO criteria: CR: disappearance of all index/non-index lesions; PR: \>= 50% reduction in the SOPD of index lesions compared with the baseline SOPD, with no evidence of progression. To qualify as CR or PR, no new lesions could be present.
Time frame: Time from first dose of study therapy to the date of PR or CR, whichever occurred first (up to 13 months).
Median Number of Months of Survival
The median number of months of survival was defined as the time from randomization to the date of death. For participants who did not die, the date of last contact was used.
Time frame: From randomization to death or date of last contact (up to 41 months).
Number of Participants With Improvement of Symptoms
Symptoms were assessed using the Functional Assessment of Cancer Therapy - Lung Cancer Subscale (FACT-LCS) questionnaire. This 7-item scale has scores ranging from 0 (severely symptomatic in all symptoms assessed) to 28 (symptom-free on all symptoms assessed). Symptom response (improvement) was defined as \>= 2-point increase from baseline in score (maintained for 2 consecutive assessments, at least 3 weeks apart). Participants with a baseline score of \>= 27 were not evaluable, as it would not have been possible to show an improvement. Participants with no baseline data were also not evaluable.
Time frame: From randomization to evidence of disease progression/death or date of last symptom assessment (up to 33 weeks).
Median Number of Months Until Symptomatic Progression (Worsening of Symptoms)
Symptoms were assessed using the FACT-LCS questionnaire. This 7-item scale has scores ranging from 0 (severely symptomatic) to 28 (symptom-free). Symptomatic progression was defined as \>= 2-point decrease from baseline in score (maintained for 2 consecutive assessments at least 3 weeks apart). Time to symptomatic progression was defined as the time from randomization to date of symptoms worsening. For participants with no symptom progression, the date of the last symptom assessment was used. See also Outcome Measure 15.
Time frame: From randomization to evidence of disease progression/death or date of last symptom assessment (up to 33 weeks).
Number of Participants Who Died, or Experienced Other Serious Adverse Events (SAEs) and Adverse Events (AEs)
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). An SAE was defined as an AE that resulted in death, was life-threatening, required hospitalization (or prolongation of existing hospitalization), or was an important medical event.
Time frame: From start of study drug therapy up to 30 days after the last dose (up to 178 weeks).
Number of Participants Experiencing AEs Leading to Study Drug Discontinuation
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). The results presented are stratified according to which drug was discontinued.
Time frame: From start of study drug therapy up to 30 days after the last dose (up to 178 weeks).
Number of Participants Experiencing Other Significant AEs: Acneform Rash
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). For this study, it was decided that AEs that were categorized under the composite term "acneform rash" were of particular importance. These AEs were: rash, rash pustular, rash erythematous, dermatitis acneiform, dermatitis exfoliative, rash papular, rash pruritic, rash generalised, rash macular, rash maculo-papular, acne, acne pustular, skin desquamation and dry skin.
Time frame: From start of study drug therapy up to 30 days after the last dose (up to 178 weeks).
Number of Participants Experiencing Other Significant AEs: Infusion Reaction
AE=any new untoward medical occurrence or worsening of pre-existing medical condition (even if not caused by the study drug). For this study, it was decided that AEs that were categorized under the composite term "infusion reaction" were of particular importance. These AEs were: infusion-related reaction, hypersensitivity, anaphylactic reaction, anaphylactic shock, and anaphylactoid reaction regardless of when they occurred. The terms dyspnea, pyrexia and chills were also grouped under infusion reaction, provided the onset date of these toxicities occurred on the first day of study treatment.
Time frame: From start of study drug therapy up to 30 days after the last dose (up to 178 weeks).
Number of Participants Experiencing Other Significant AEs: Cardiac AEs
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). For this study, it was decided that AEs that were categorized under the composite term "cardiac AE" were of particular importance. These AEs, coded as preferred or other level Medical Dictionary for Regulatory Activities \[MedDRA\] terms were: coronary artery disorders, cardiac arrhythmias, heart failures not elsewhere classified, left ventricular failures, sudden cardiac death, cardiac death and sudden death.
Time frame: From start of study drug therapy up to 30 days after the last dose (up to 178 weeks).
Number of Participants Who Exprienced the Most Frequent Grade 3-4 Hematology Abnormalities Occurring in >=5% Participants
Abnormalities were graded according to the National Cancer Institute (NCI) Common Toxicity Criteria (CTC), version 3.0. The scale is graded from 1 (least severe) to 4 (life threatening). Grade 3 and 4 criteria are defined as follows: Neutropenia: Grade 3, neutrophils \<1.0 - 0.5 x 10\^9/L; Grade 4, \<0.5 x 10\^9/L. Leukopenia: Grade 3, leukocytes \<2.0 - 1.0 x 10\^9/L; Grade 4, \<1.0 x 10\^9/L. Thrombocytopenia: Grade 3, platelets \<50.0 - 25.0 x 10\^9/L; Grade 4, \<25.0 x 10\^9/L. Anemia: Grade 3, hemoglobin \<4.9 - 4.0 millimoles (mmol)/L, Grade 4, \<4.0 mmol/L.
Time frame: From start of study drug therapy up to 30 days after the last dose (up to 178 weeks).
Number of Participants Who Experienced the Most Frequent Grade 3-4 Serum Chemistry Abnormalities Occurring in >=5% Participants
Abnormalities were graded according to the NCI CTC, version 3.0. The scale is graded from 1 (least severe) to 4 (life threatening). Grade 3 and 4 criteria are defined as follows: Hyperglycemia (non-fasting): Grade 3, serum glucose \>13.9 - 27.8 mmol/L; Grade 4 \>27.8 mmol/L or acidosis. Hypomagnesemia: Grade 3, serum magnesium \>1.23 - 3.30 mmol/L; Grade 4 \>3.30 mmol/L. Hyponatremia: Grade 3, serum sodium \<130 - 120 mmol/L; Grade 4 \<120 mmol/L. Low albumin: Grade 3, serum albumin \<20 g/L; Grade 4 not applicable.
Time frame: From start of study drug therapy up to 30 days after the last dose (up to 178 weeks).
Number of Participants Who Had Unscheduled Visits to Physicians, Clinics, Hospitals and Other Unscheduled Major Medicinal Procedures
Participants were to complete log to collect information on unscheduled visits to physicians,clinics,hospitals \& other unscheduled major procedures.If asked, participants were to complete and return log to site upon routinely scheduled visits.The purpose of this exploratory analysis was to understand the economical implications as a secondary objective.This was not a pivotal study \& therefore not needed to support any arguments with regulatory authorities concerning cost-benefit,hence,it was not necessary to conduct this analysis. There is no intent on conducting this analysis in the future.
Time frame: Day 1 of each cycle of treatment, at the end of study therapy evaluation and at the first follow-up visit (6 weeks after the end of study therapy evaluation).
Median Change From Baseline in Symptoms, by Time Point
Symptoms were assessed using the FACT-LCS questionnaire. This 7-item scale has scores ranging from 0 (severely symptomatic) to 28 (symptom-free). The median change from baseline score was calculated at 3-weekly intervals. See also Outcome Measure 8.
Time frame: From randomization to evidence of disease progression/death or date of last symptom assessment (up to 33 weeks).
| Milestone | Cetuximab+Taxane+Carboplatin (C/T/C) | Taxane+Carboplatin (T/C) |
|---|---|---|
| Started | 325 | 320 |
| Never treated | 13 | 18 |
| Completed | 320 | 320 |
| Not completed | 5 | 0 |
| Withdrew: Still on study | 5 | 0 |
Interval between randomization date \& earliest date of disease progression/death due to any cause, assessed by the Independent Radiology Review Committee (IRRC) using modified World Health Organization (WHO) criteria to define progressive disease (PD): \>=25% increase in sum of products of diameters (SOPD) of lesions compared with smallest SOPD recorded for study period or progression of any non-index lesion/appearance of new lesion. If no progression/death, date of last tumor assessment used. For participants who had no on-study tumor assessments \& were still alive, date of randomization used.
| Months | Cetuximab+Taxane+Carboplatin (C/T/C) | Taxane+Carboplatin (T/C) |
|---|---|---|
| Median Number of Months of Progression-free Survival (PFS) | 4.40 (4.11 to 5.06) | 4.24 (3.94 to 4.63) |
Tumor response was defined as the number of participants whose best response was CR or PR, per the IRRC assessment, using the modified WHO criteria: CR: disappearance of all index/non-index lesions; PR: \>= 50% reduction in the SOPD of index lesions compared with the baseline SOPD, with no evidence of progression. To qualify as CR or PR, no new lesions could be present.
| Participants | Cetuximab+Taxane+Carboplatin (C/T/C) | Taxane+Carboplatin (T/C) |
|---|---|---|
| Number of Participants With Complete Response (CR) or Partial Response (PR) | 87 | 58 |
Disease control was defined as the number of participants whose best response was CR, PR, or SD, per the IRRC assessment, using the modified WHO criteria: CR: disappearance of all index/non-index lesions; PR:\>= 50% reduction in the SOPD of index lesions compared with the baseline SOPD, with no evidence of progression (to qualify as CR or PR, no new lesions could be present); SD: participants who did not meet the criteria for CR, PR, or PD (PD:\>=25% increase in SOPD of lesions compared with smallest SOPD recorded for study period or progression of any non-index lesion/appearance of new lesion).
| Participants | Cetuximab+Taxane+Carboplatin (C/T/C) | Taxane+Carboplatin (T/C) |
|---|---|---|
| Number of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD) | 230 | 212 |
Median number of months of response (time from first occurrence of CR/PR to date of PD/death, \[per IRRC assessment,using modified WHO criteria\]) calculated for participants whose best response=CR/PR.For participants who did not progress/die, date of last tumor assessment used.CR:disappearance of all index/non-index lesions;PR:\>= 50% reduction in SOPD of index lesions compared with baseline, no evidence of progression.No new lesions present.PD:\>=25% increase in SOPD of lesions compared with smallest SOPD recorded for study period or progression of any non-index lesion/appearance of new lesion.
| Months | Cetuximab+Taxane+Carboplatin (C/T/C) | Taxane+Carboplatin (T/C) |
|---|---|---|
| Median Number of Months of Response | 5.55 (4.40 to 6.83) | 4.90 (4.24 to 5.72) |
The median number of months to response was calculated for participants whose best response was CR or PR. It was defined as the time from the first dose of study therapy to the first date that criteria for PR or CR (whichever occurred first)were met. Response was assessed by the IRRC, using the modified WHO criteria: CR: disappearance of all index/non-index lesions; PR: \>= 50% reduction in the SOPD of index lesions compared with the baseline SOPD, with no evidence of progression. To qualify as CR or PR, no new lesions could be present.
| Months | Cetuximab+Taxane+Carboplatin (C/T/C) | Taxane+Carboplatin (T/C) |
|---|---|---|
| Median Number of Months to Response | 1.38 (1.08 to 12.65) | 1.35 (0.99 to 4.83) |
The median number of months of survival was defined as the time from randomization to the date of death. For participants who did not die, the date of last contact was used.
| Months | Cetuximab+Taxane+Carboplatin (C/T/C) | Taxane+Carboplatin (T/C) |
|---|---|---|
| Median Number of Months of Survival | 9.69 (8.28 to 11.50) | 8.38 (7.33 to 9.92) |
Symptoms were assessed using the Functional Assessment of Cancer Therapy - Lung Cancer Subscale (FACT-LCS) questionnaire. This 7-item scale has scores ranging from 0 (severely symptomatic in all symptoms assessed) to 28 (symptom-free on all symptoms assessed). Symptom response (improvement) was defined as \>= 2-point increase from baseline in score (maintained for 2 consecutive assessments, at least 3 weeks apart). Participants with a baseline score of \>= 27 were not evaluable, as it would not have been possible to show an improvement. Participants with no baseline data were also not evaluable.
| Participants | Cetuximab+Taxane+Carboplatin (C/T/C) | Taxane+Carboplatin (T/C) |
|---|---|---|
| Number of Participants With Improvement of Symptoms | 107 | 92 |
Symptoms were assessed using the FACT-LCS questionnaire. This 7-item scale has scores ranging from 0 (severely symptomatic) to 28 (symptom-free). Symptomatic progression was defined as \>= 2-point decrease from baseline in score (maintained for 2 consecutive assessments at least 3 weeks apart). Time to symptomatic progression was defined as the time from randomization to date of symptoms worsening. For participants with no symptom progression, the date of the last symptom assessment was used. See also Outcome Measure 15.
No measurements were reported for this outcome.
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). An SAE was defined as an AE that resulted in death, was life-threatening, required hospitalization (or prolongation of existing hospitalization), or was an important medical event.
| Participants | Cetuximab+Taxane+Carboplatin (C/T/C) | Taxane+Carboplatin (T/C) |
|---|---|---|
| Death | 38 | 27 |
| Serious adverse events | 183 | 121 |
| Adverse events | 324 | 320 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). The results presented are stratified according to which drug was discontinued.
| participants | Cetuximab+Taxane+Carboplatin (C/T/C) | Taxane+Carboplatin (T/C) |
|---|---|---|
| Cetuximab | 100 | 0 |
| Taxane | 80 | 54 |
| Carboplatin | 78 | 52 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). For this study, it was decided that AEs that were categorized under the composite term "acneform rash" were of particular importance. These AEs were: rash, rash pustular, rash erythematous, dermatitis acneiform, dermatitis exfoliative, rash papular, rash pruritic, rash generalised, rash macular, rash maculo-papular, acne, acne pustular, skin desquamation and dry skin.
| Participants | Cetuximab+Taxane+Carboplatin (C/T/C) | Taxane+Carboplatin (T/C) |
|---|---|---|
| Number of Participants Experiencing Other Significant AEs: Acneform Rash | 246 | 56 |
AE=any new untoward medical occurrence or worsening of pre-existing medical condition (even if not caused by the study drug). For this study, it was decided that AEs that were categorized under the composite term "infusion reaction" were of particular importance. These AEs were: infusion-related reaction, hypersensitivity, anaphylactic reaction, anaphylactic shock, and anaphylactoid reaction regardless of when they occurred. The terms dyspnea, pyrexia and chills were also grouped under infusion reaction, provided the onset date of these toxicities occurred on the first day of study treatment.
| Participants | Cetuximab+Taxane+Carboplatin (C/T/C) | Taxane+Carboplatin (T/C) |
|---|---|---|
| Number of Participants Experiencing Other Significant AEs: Infusion Reaction | 45 | 18 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). For this study, it was decided that AEs that were categorized under the composite term "cardiac AE" were of particular importance. These AEs, coded as preferred or other level Medical Dictionary for Regulatory Activities \[MedDRA\] terms were: coronary artery disorders, cardiac arrhythmias, heart failures not elsewhere classified, left ventricular failures, sudden cardiac death, cardiac death and sudden death.
| Participants | Cetuximab+Taxane+Carboplatin (C/T/C) | Taxane+Carboplatin (T/C) |
|---|---|---|
| Number of Participants Experiencing Other Significant AEs: Cardiac AEs | 58 | 25 |
Abnormalities were graded according to the National Cancer Institute (NCI) Common Toxicity Criteria (CTC), version 3.0. The scale is graded from 1 (least severe) to 4 (life threatening). Grade 3 and 4 criteria are defined as follows: Neutropenia: Grade 3, neutrophils \<1.0 - 0.5 x 10\^9/L; Grade 4, \<0.5 x 10\^9/L. Leukopenia: Grade 3, leukocytes \<2.0 - 1.0 x 10\^9/L; Grade 4, \<1.0 x 10\^9/L. Thrombocytopenia: Grade 3, platelets \<50.0 - 25.0 x 10\^9/L; Grade 4, \<25.0 x 10\^9/L. Anemia: Grade 3, hemoglobin \<4.9 - 4.0 millimoles (mmol)/L, Grade 4, \<4.0 mmol/L.
| Participants | Cetuximab+Taxane+Carboplatin (C/T/C) | Taxane+Carboplatin (T/C) |
|---|---|---|
| Neutropenia | 198 | 177 |
| Leukopenia | 139 | 97 |
| Thrombocytopenia | 33 | 29 |
| Anemia | 17 | 15 |
Symptoms were assessed using the FACT-LCS questionnaire. This 7-item scale has scores ranging from 0 (severely symptomatic) to 28 (symptom-free). The median change from baseline score was calculated at 3-weekly intervals. See also Outcome Measure 8.
| Units on a scale | Cetuximab+Taxane+Carboplatin (C/T/C) | Taxane+Carboplatin (T/C) |
|---|---|---|
| 3 weeks (n = 286, 257) | 1.0 (-1.0 to 3.0) | 0.8 (-2.0 to 3.0) |
| 6 weeks (n = 254, 221) | 1.0 (-2.0 to 4.0) | 1.0 (-2.0 to 4.0) |
| 9 weeks (n = 203, 175) | 1.0 (-2.0 to 4.0) | 1.0 (-2.0 to 4.0) |
| 12 weeks (n = 178, 161) | 1.0 (-2.0 to 4.0) | 0.0 (-2.0 to 4.0) |
| 15 weeks (n = 155, 121) | 1.0 (-2.0 to 4.0) | 1.0 (-2.0 to 5.0) |
| 18 weeks (n = 126, 91) | 1.0 (-1.0 to 4.0) | 2.0 (-2.0 to 5.0) |
| 21 weeks (n = 96, 43) | 2.0 (-1.0 to 4.0) | 3.0 (-1.0 to 7.0) |
| 24 weeks (n = 90, 41) | 2.0 (-2.0 to 5.0) | 1.0 (-1.0 to 5.0) |
| 27 weeks (n = 60, 22) | 3.0 (-1.0 to 5.0) | 3.5 (-1.0 to 7.0) |
| 30 weeks (n = 56, 15) | 1.5 (-1.0 to 5.0) | 3.0 (0.0 to 5.0) |
| 33 weeks (n = 43, 7) | 2.1 (-1.0 to 6.0) | 3.0 (-1.0 to 8.0) |
Abnormalities were graded according to the NCI CTC, version 3.0. The scale is graded from 1 (least severe) to 4 (life threatening). Grade 3 and 4 criteria are defined as follows: Hyperglycemia (non-fasting): Grade 3, serum glucose \>13.9 - 27.8 mmol/L; Grade 4 \>27.8 mmol/L or acidosis. Hypomagnesemia: Grade 3, serum magnesium \>1.23 - 3.30 mmol/L; Grade 4 \>3.30 mmol/L. Hyponatremia: Grade 3, serum sodium \<130 - 120 mmol/L; Grade 4 \<120 mmol/L. Low albumin: Grade 3, serum albumin \<20 g/L; Grade 4 not applicable.
| Participants | Cetuximab+Taxane+Carboplatin (C/T/C) | Taxane+Carboplatin (T/C) |
|---|---|---|
| Hyperglycemia (non-fasting) | 33 | 36 |
| Hypomagnesemia | 26 | 2 |
| Hyponatremia | 25 | 21 |
| Low albumin | 17 | 9 |
Participants were to complete log to collect information on unscheduled visits to physicians,clinics,hospitals \& other unscheduled major procedures.If asked, participants were to complete and return log to site upon routinely scheduled visits.The purpose of this exploratory analysis was to understand the economical implications as a secondary objective.This was not a pivotal study \& therefore not needed to support any arguments with regulatory authorities concerning cost-benefit,hence,it was not necessary to conduct this analysis. There is no intent on conducting this analysis in the future.
No measurements were reported for this outcome.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cetuximab+Taxane+Carboplatin | — | 183/325 (56.3%) | 322/325 (99.1%) |
| Taxane+Carboplatin | — | 121/320 (37.8%) | 317/320 (99.1%) |
| Event | Cetuximab+Taxane+Carboplatin | Taxane+Carboplatin |
|---|---|---|
| DehydrationMetabolism and nutrition disorders | 24/325 | 11/320 |
| PneumoniaInfections and infestations | 18/325 | 11/320 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 15/325 | 11/320 |
| Febrile neutropeniaBlood and lymphatic system disorders | 14/325 | 8/320 |
| HypersensitivityImmune system disorders | 11/325 | 1/320 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 10/325 | 8/320 |
| Neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 9/325 | 4/320 |
| NeutropeniaBlood and lymphatic system disorders | 9/325 | 4/320 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 9/325 | 7/320 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 8/325 | 4/320 |
| Event | Cetuximab+Taxane+Carboplatin | Taxane+Carboplatin |
|---|---|---|
| FatigueGeneral disorders | 243/325 | 228/320 |
| NauseaGastrointestinal disorders | 198/325 | 161/320 |
| RashSkin and subcutaneous tissue disorders | 186/325 | 47/320 |
| DiarrhoeaGastrointestinal disorders | 156/325 | 105/320 |
| ConstipationGastrointestinal disorders | 147/325 | 99/320 |
| AlopeciaSkin and subcutaneous tissue disorders | 118/325 | 141/320 |
| AnorexiaMetabolism and nutrition disorders | 131/325 | 97/320 |
| VomitingGastrointestinal disorders | 107/325 | 93/320 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 106/325 | 104/320 |
| CoughRespiratory, thoracic and mediastinal disorders | 100/325 | 81/320 |
| Age, Continuous(years) | Cetuximab+Taxane+Carboplatin (C/T/C) | Taxane+Carboplatin (T/C) | Total |
|---|---|---|---|
| Mean | 64.0 ± 10.0 | 63.9 ± 10.3 | 64.0 ± 10.2 |
| Age, Customized(participants) | Cetuximab+Taxane+Carboplatin (C/T/C) | Taxane+Carboplatin (T/C) | Total |
|---|---|---|---|
| <65 years | 171 | 165 | 336 |
| >= 65 years | 167 | 173 | 340 |
| Sex: Female, Male(Participants) | Cetuximab+Taxane+Carboplatin (C/T/C) | Taxane+Carboplatin (T/C) | Total |
|---|---|---|---|
| Female | 146 | 134 | 280 |
| Male | 192 | 204 | 396 |
| Race/Ethnicity, Customized(Participants) | Cetuximab+Taxane+Carboplatin (C/T/C) | Taxane+Carboplatin (T/C) | Total |
|---|---|---|---|
| Asian | 6 | 10 | 16 |
| Black | 25 | 24 | 49 |
| White | 296 | 300 | 596 |
| Other race | 11 | 4 | 15 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)(Participants) | Cetuximab+Taxane+Carboplatin (C/T/C) | Taxane+Carboplatin (T/C) | Total |
|---|---|---|---|
| 0=fully active | 110 | 114 | 224 |
| 1=restricted physically strenuous activity | 221 | 220 | 441 |
| 2=ambulatory but unable to work | 4 | 2 | 6 |
| 3=capable of only limited self care | 0 | 1 | 1 |
| 4=completely disabled | 0 | 0 | 0 |
| 5=dead | 0 | 0 | 0 |
| Missing | 3 | 1 | 4 |
| Weight(kg) | Cetuximab+Taxane+Carboplatin (C/T/C) | Taxane+Carboplatin (T/C) | Total |
|---|---|---|---|
| Mean | 75.0 ± 17.1 | 75.3 ± 18.1 | 75.1 ± 17.6 |
Showing the first 100 of 125 sites. Choose a country and city above to see the rest.
The record gives a start of Dec 2004, a primary completion of Apr 2007 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2010, 3 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cetuximab
Carcinoma, Non-Small-Cell Lung →